Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ambry Genetics Corp.

Division of Konica Minolta Inc.
www.ambrygen.com

Latest From Ambry Genetics Corp.

Device/Diagnostics Quarterly Deal-Making Statistics, Q4 2017

Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.

Deals Market Intelligence

Diagnostics 2018: Steady Progress And The Big Get Bigger

If the beginning of 2017 was marked by doubts around whether and how the FDA would act with respect to complex diagnostics, we enter 2018 feeling that slow-moving vessel may finally be turning.

Medical Device Diagnostics

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017

Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.

Medical Device In Vitro Diagnostics

Deals Shaping the Medical Industry, August 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Laboratory Testing Services
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Konica Minolta Inc.
  • Senior Management
  • Aaron Elliott, PhD, CEO
    Michael Martinson, CFO
    Brigette Tippin Davis, PhD, VP, R&D
    Charles Dunlop, Pres.
    Tom Schoenherr, Chief Commercial Officer
  • Contact Info
  • Ambry Genetics Corp.
    Phone: (949) 900-5500
    15 Argonaut
    Aliso Viejo, CA 92656
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register